Icade SA (0K4O)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 14.59 |
|---|---|
| 52-week range | 14.22 – 22.78 |
| Return, 1 month / 3 months | −12.3% / −23.7% |
| Return, 1 year / 3 years | −31.2% / −26.3% |
| Trend | Below its 200-day average |
| RSI (14) | 32 |
| Volatility (1 year) | 24.1% |
| Worst drawdown (1 year) | -34.6% |
| Average daily value traded | 0.20M EUR |
| Dividend yield | 4.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Icade is a French real estate company based in Paris. It operates as a real estate investment trust with activities spanning property investment, property development and healthcare property. Its investment business owns and manages office and business park properties, while its development arm designs and builds residential, office and public-sector projects. The healthcare division invests in clinics and care facilities. Its customers include companies, public bodies and healthcare operators, mainly in France.
The shares are listed on the London Exchange in UK under the code 0K4O, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Icade SA (0K4O) trades on the London Exchange in UK. It last closed at EUR 14.59 on 23 October 2026.
Its price-based Market X-Ray is 33 out of 100 (a weak price profile), ranking 2,938 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 31.2% and over the last three months it fell 23.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 17 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -23.1% | ||
| From 52-week high | -35.4% | ||
| Momentum | 14 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -23.7% | ||
| 6-month return | -27.5% | ||
| 12-month return, skipping the last month | -21.6% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 24.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.6% | ||
| Liquidity | 37 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.20M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | 54 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.1% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −1.6% |
|---|---|
| 1 month | −12.3% |
| 3 months | −23.7% |
| 6 months | −27.5% |
| 1 year | −31.2% |
| 3 years | −26.3% |
| 5 years | −64.7% |
Signals
| 50-day / 200-day average | 16.63 / 18.96 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.49 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Jun 2026 | EUR 0.6033 |
| 1 Jul 2025 | EUR 2.1500 |
| 4 Mar 2025 | EUR 1.0000 |
| 2 Jul 2024 | EUR 2.4200 |
| 4 Mar 2024 | EUR 2.4200 |
| 4 Jul 2023 | EUR 1.6600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.